VP-63843. Antiviral

Drugs of the Future

Volumn 22, Issue 1, 1997, Pages 40-44

  Fromtling, R A ^a   Castaner J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; PLECONARIL; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; DRUG SYNTHESIS; HUMAN; NONHUMAN; ORAL DRUG ADMINISTRATION; PICORNAVIRUS; RNA VIRUS; SHORT SURVEY; VIRUS INFECTION; VIRUS REPLICATION;

EID: 1842293317     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1997.022.01.390204     Document Type: Short Survey

References (18)

1. Diana, G.D., Nitz, T.J. (Sterling Winthrop, Inc.). 1,2,4-Oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral agents. EP 566199, JP 94049066, US 5349068.
2. Diana, G.D., Nitz, T.J. (Sterling Winthrop, Inc.). 1,2,4-Oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral agents. US 5464848.
3. Diana, G.D., Rudewicz, P., Pevear, D.C. et al. Picornavirus inhibitors: Trifluoromethyl substitution provides a global protective effect against hepatic metabolism. J Med Chem 1995, 38: 1355-71.
4. Merck Manual of Diagnosis and Therapy, 16th Edition, R. Berkow (Ed.), Merck Research Laboratories, Rahway, NJ, 1992, 204-5.
5. Rotbart, H.A. Enteroviruses. In: Manual of Clinical Microbiology, 6th Edition, P.R. Murray, E.J. Barron, M.A. Pfaller, F.C. Tenover, R.H. Yolken (Eds.), ASM Press, Washington DC, 1995, 1004-11.
6. Landry, M.L. Rhinoviruses. In: Manual of Clinical Microbiology, 6th Edition, P.R. Murray, E.J. Barron, M.A. Pfaller, F.C. Tenover, R.H. Yolken (Eds.), ASM Press, Washington DC, 1995, 940-6.
7. Strikas, R.A., Anderson, L.J., Parker, R.A. Temporal and geographic patterns of isolates of nonpolio enterovirus in the United States, 1973-1983. J Infect Dis 1986, 153: 346-51.
8. Yin-Murphy, M. Acute hemorrhagic conjunctivitis. Prog Med Virol 1984, 29: 43-4.
9. Hogle, J.M., Chow, M., Filman, D.J. Three-dimensional structure of poliovirus at 2.9 A resolution. Science 1985, 229: 1358-65.
10. Rossmann, M.G., Arnold, E., Erickson, E.A., Frankenberger, E.A., Griffith, J.P., Hecht, H.-J., Johnson, J.E., Kamer, G. Structure of a human common cold virus and functional relationship to other picornaviruses. Nature 1985, 317: 145-53.
11. Rueckert, R.R. Picornaviridae and their replication. In: Virology, B.N. Fields, D.M. Knipe (Eds.), Raven Press, New York, 1990, 507-48.
12. Diana, G.D., Rudewicz, P., Pevear, D.C. et al. WIN 63843, a metabolically stable broad spectrum antipicornaviral compound. Antiviral Res 1995, 26(3): Abst 227.
13. Diana, G. Antiviral drug design based on X-ray crystallography. IBC 2nd Annu Antivir Conf (Nov 17-18, Washington DC) 1994.
14. Dutko, F., Oppermann, J., Robinson, D., Block, T., Czerniak, R., McKinlay, M., Jaeger, E., Nitz, T.J., Diana, G., Pevear, D. Preclinical activity and pharmacokinetics of WIN 63843, a metabolically stable inhibitor of human picornaviruses. IBC 2nd Annu Antivir Conf (Nov 17-18, Washington DC) 1994.
15. Rocco, W.L., Swanson, J.R. WIN 63843 polymorphs. Prediction of enantiotrophy. Int J Pharm 1995, 117: 231-6.
16. Groarke, J.M., McKinlay, M.A., Dutko, F.J., Pevear, D.C. Coxsackievirus B3 mutants resistant to WIN 63843 are attenuated for virulence in mice: Molecular aspects of the drug restant phenotype. Antivir Res 1995, 26(3): Abst 139.
17. Pevear, D.C., Seipei, M.E., Pallansch, M., McKinlay, M.A. In vitro activity of VP 63843 against field isolates of non-polio enteroviruses. 36th Intersci Conf Antimicrob Agents Chemother (Sept 15-18, New Orleans) 1996, Abst H99.
18. Schiff, G.M., McKinlay, M.A., Sherwood, J.R. Oral efficacy of VP 63843 in coxsackievirus A21 infected volunteers. 36th Intersci Conf Antimicrob Agents Chemother (Sept 15-18, New Orleans) 1996, Abst H43.